KORU Medical Systems, Inc. (KRMD)
| Market Cap | 175.92M +39.2% |
| Revenue (ttm) | 43.26M +23.3% |
| Net Income | -2.28M |
| EPS | -0.05 |
| Shares Out | 45.93M |
| PE Ratio | n/a |
| Forward PE | 109.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,250 |
| Open | 3.880 |
| Previous Close | 3.900 |
| Day's Range | 3.830 - 4.020 |
| 52-Week Range | 2.625 - 6.608 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 6.80 (+77.55%) |
| Earnings Date | May 6, 2026 |
About KRMD
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver,... [Read more]
Financial Performance
In 2025, KORU Medical Systems's revenue was $41.13 million, an increase of 22.23% compared to the previous year's $33.65 million. Losses were -$2.64 million, -56.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for KRMD stock is "Strong Buy." The 12-month stock price target is $6.8, which is an increase of 77.55% from the latest price.
News
Koru Medical reports Q1 revenue $11.77M, consensus $11.28M
16:14 EDT Koru Medical (KRMD) reports Q1 revenue $11.77M, consensus $11.28M
Koru Medical affirms FY26 revenue view $47.5M-$50M, consensus $48.52M
16:14 EDT Koru Medical (KRMD) affirms FY26 revenue view $47.5M-$50M, consensus $48.52M
KORU Medical Systems Earnings Call Transcript: Q1 2026
Q1 2026 delivered 22% revenue growth, strong domestic and international expansion, and improved profitability metrics. Guidance for the full year is reiterated, with expectations for continued growth, positive cash flow, and margin improvement as new markets and products ramp.
KORU Medical Systems Announces First Quarter 2026 Results
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
MAHWAH, NJ--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializat...
Koru Medical price target raised to $8 from $7 at B. Riley
B. Riley raised the firm’s price target on Koru Medical (KRMD) to $8 from $7 and keeps a Buy rating on the shares. Following the Q4 earnings report, B. Riley…
KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems Earnings Call Transcript: Q4 2025
Revenue grew 22% year-over-year to $41.1M in 2025, with strong domestic and international gains, positive adjusted EBITDA, and cash flow. 2026 guidance projects 15%–22% revenue growth, continued profitability, and new product launches, amid a CEO transition.
Koru Medical CEO Tharby to retire
Koru Medical (KRMD) Systetms announced that following five years of service to the Company, Linda Tharby, President and Chief Executive Officer, will retire effective June 30, 2026. The Board of…
KORU Medical Systems Announces CEO Transition
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
Koru Medical gets 510k clearance for delivery of Rystiggo
KORU Medical (KRMD) “announced that the Company received U.S. Food and Drug Administration clearance for use of the KORU Medical FreedomEDGE(R) infusion system to deliver RYSTIGGO, a therapy commercia...
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
Koru Medical price target raised to $7 from $6.25 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Koru Medical (KRMD) to $7 from $6.25 and keeps a Buy rating on the shares following the company’s Q4 pre-release. While exact contribution…
KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercializat...
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
Koru Medical submits FreedomEDGE 510(k) premarket notification to the FDA
Koru Medical (KRMD) announced the submission of a 510(k) premarket notification to the FDA seeking clearance for the use of Koru Medical’s FreedomEDGE infusion system to subcutaneously administer Phes...
KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
Koru Medical price target raised to $8 from $6 at Lake Street
Lake Street raised the firm’s price target on Koru Medical (KRMD) to $8 from $6 and keeps a Buy rating on the shares. The firm, which thinks a 510K submission…
Koru Medical price target raised to $6 from $5 at Canaccord
Canaccord raised the firm’s price target on Koru Medical (KRMD) to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model to reflect their…
Koru Medical names Eric Schiller CTO
Koru Medical (KRMD) announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across...
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercializa...
KORU Medical Systems Transcript: Piper Sandler 37th Annual Healthcare Conference
Year-to-date growth exceeded 20%, fueled by international expansion, U.S. market outperformance, and prefill technology. New drugs and products are set to drive further gains, with margin improvement and cash flow positivity supporting a robust outlook.
KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume ...